KANSL2

Across TCGA pan-cancer cohorts, KANSL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KANSL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KANSL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KANSL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where KANSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.908	0.504	.001	30	view →
LUAD	OS	Quartile	II,III,IV	0.751	0.422	.038	6	view →
GBM	OS	Quartile	All	0.621	0.374	.027	4	view →
LSCC	OS	Quartile	All	0.954	0.767	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KANSL2–PDAC (DFS)

Open the PDAC breakdown →